Is 2025 a pivotal inflection point for AI in health care? Dr. Connie Lehman, Co-Founder of Clairity, thinks so, and she has strong cause for optimism. Her organization’s software-as-a-medical-device product, Clairity Breast, recently received authorization from the Food and Drug Administration as the first AI platform that predicts a woman’s five-year risk of developing breast cancer.
On this episode, Dr. Lehman shares her journey with Clairity, from the paper she read as a medical student that sparked the idea, to her experience navigating the new domain of image-based risk assessment with the FDA. Her current focus is on implementing the technology through education and advocacy.
Dr. Lehman is passionate about advancing medicine toward risk assessment and disease prevention. Understanding risk empowers patients and their health care providers to choose the best path. Dr. Lehman envisions a future where image-based risk information is accessible and available to improve health outcomes for all.
